The Reality of Compounded Tirzepatide After the 2024 Shortage Resolution

The Reality of Compounded Tirzepatide After the 2024 Shortage Resolution is best understood as a clinical decision topic, not a shortcut. The evidence, pharmacy source, dose plan, contraindications, and follow-up matter more than any single success story online.

A friend of mine, a nurse practitioner in suburban Dallas who runs a weight management clinic, told me last February that she’d fielded eleven calls in a single week from patients asking the same question: “Can I still get compounded tirzepatide now that the shortage is over?” She said her answer was always the same. “You can. But you need to understand what you’re actually buying, because it’s not the same thing as picking up Zepbound at Walgreens.”

That distinction is where most of the confusion lives. So let’s take it apart.

What Compounded Tirzepatide Actually Is (and Isn’t)

Compounded tirzepatide is a prescription medication prepared by a licensed 503A or 503B pharmacy using tirzepatide as the active ingredient. A prescriber writes the script; a compounding pharmacist fills it. The molecule is the same one in Mounjaro and Zepbound, Eli Lilly’s FDA-approved branded products.

But “same molecule” does not mean “same product.” The manufacturing pathway, the quality oversight, the packaging, and the regulatory status are all different. Compounded preparations are not FDA-evaluated for safety, efficacy, or quality the way branded drugs are. They exist under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act and are regulated through a combination of state pharmacy boards and, for 503B facilities, direct FDA registration and cGMP inspection.

The boring truth is that the active pharmacology is identical at the receptor level while almost everything surrounding it (who made it, how it was tested, what label it carries) is not. Patients who understand that distinction make better decisions. Patients who don’t tend to get surprised later.

The Shortage Ended. The Compounding Didn’t.

FDA declared the tirzepatide shortage resolved in December 2024, and the semaglutide shortage resolved in February 2025. That changed the regulatory posture for compounding, but it didn’t shut the door entirely.

Under the current framework, 503A pharmacies can still compound patient-specific tirzepatide preparations when clinical necessity is documented and a valid prescription exists. 503B outsourcing facilities, which are FDA-registered and operate under cGMP standards similar to traditional manufacturers, can produce office stock not tied to a specific patient prescription at the time of preparation.

Where this falls apart for some patients is the assumption that “shortage resolved” means “compounding is illegal now.” It doesn’t. It means the regulatory scrutiny around compounding has tightened, and the justification requirements are more specific. Reputable telehealth providers adapted. Fly-by-night ones got quieter or disappeared.

How Tirzepatide Works, Briefly

Tirzepatide is a dual agonist. It hits both the GIP receptor (glucose-dependent insulinotropic polypeptide) and the GLP-1 receptor (glucagon-like peptide-1). That dual action is why it consistently outperforms semaglutide in head-to-head data, most recently in SURMOUNT-5.

GLP-1 receptor activation in the brainstem and vagal afferents reduces appetite signaling and slows gastric emptying. GIP receptor co-activation appears to potentiate the weight loss effect beyond what GLP-1 alone achieves.

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) reported mean weight reductions of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks in adults with obesity. Those are population averages; individual responses ranged widely, with some participants losing over 25% and others under 10%.

None of this changes between branded and compounded formulations. The molecule doesn’t know what building it was synthesized in. The differences live upstream, in manufacturing controls and regulatory scrutiny, not downstream at the receptor.

The 503A vs. 503B Distinction Matters More Than Most Patients Realize

Think of it like the difference between a custom-built house and a tract home. A 503A pharmacy compounds patient-specific medications, one prescription at a time, with state board oversight and federal requirements layered on top. A 503B outsourcing facility operates more like a small-scale manufacturer: FDA-registered, cGMP-inspected, able to produce batches in advance.

The Agency for Healthcare Research and Quality and FDA guidance distinguish these pathways clearly. Both involve oversight, but the type and intensity differ.

For patients comparing telehealth providers, the practical question is simple: does the provider disclose which type of pharmacy partner they use? If they don’t, that’s a red flag worth taking seriously.

Dosing: The Ramp Matters

Standard tirzepatide dosing starts at 2.5 mg weekly for four weeks. This is the tolerance phase. You’re training your GI system to handle the drug, not losing meaningful weight.

The first real therapeutic dose is 5 mg weekly (weeks 5 through 8). This is where most patients notice genuine appetite suppression, not just mild nausea.

From there, titration proceeds through 7.5, 10, 12.5, and up to 15 mg at four-week intervals, based on tolerance and response. Not every patient needs to reach 15 mg. Many stabilize at 5 to 10 mg once they hit their target weight, balancing ongoing benefit against side effects and cost.

| Phase | Typical Dose | Duration | Notes | |—|—|—|—| | Initiation | 2.5 mg weekly | Weeks 1-4 | GI tolerance phase, minimal weight loss expected | | Step 1 | 5 mg weekly | Weeks 5-8 | First meaningful appetite reduction | | Step 2 | 7.5 mg weekly | Weeks 9-12 | Some patients hold here if response is adequate | | Step 3 | 10 mg weekly | Weeks 13-16 | Common long-term maintenance tier | | Step 4 | 12.5 mg weekly | Weeks 17-20 | For patients with attenuating response | | Step 5 | 15 mg weekly | Week 21+ | Maximum labeled dose; many never need it |

One practical advantage of compounded preparations: intermediate doses like 6.25 or 8.75 mg are possible, which branded autoinjectors don’t offer. When a patient tolerates 5 mg fine but gets knocked flat by 7.5 mg, that flexibility can be the difference between staying on therapy and quitting.

What It Costs in 2026

Branded Zepbound retails at roughly $1,059 per month without insurance. Eli Lilly’s LillyDirect self-pay vial program brings that down to $499 monthly for eligible patients at certain doses, though you have to meet their criteria.

Compounded tirzepatide through reputable telehealth pathways runs $197 to $397 per month, depending on dose, provider, and whether you commit to a multi-month term. This is cash-pay. Insurance doesn’t cover compounded preparations because they aren’t FDA-approved finished drugs.

| Format | Monthly Cash Range | Notes | |—|—|—| | Branded Zepbound (cash) | $1,059 retail; $499 via LillyDirect | Self-pay vial pathway has eligibility criteria | | Branded Mounjaro (copay card) | $25-$573 with eligibility | Off-label weight loss use typically not covered | | Compounded tirzepatide (503A) | $197-$397 | Patient-specific, prescription required | | Compounded tirzepatide (503B) | Varies by clinic | Clinic-administered or distributed |

HSA and FSA funds are typically eligible for prescription compounded medications with proper documentation. Keep your itemized receipts.

A word on commitment terms: quarterly and six-month plans usually offer per-month savings, but read the auto-renewal clauses and cancellation policies before you sign. I’ve seen patients locked into plans they couldn’t exit without forfeiting a payment. That’s not a clinical problem, it’s a consumer protection one, but it still matters.

For patients who want a structured walkthrough of the regulatory framework, dosing protocols, and monitoring expectations, FormBlends maintains a detailed reference guide. It’s worth reading alongside (not instead of) whatever your telehealth provider sends you.

When to Call Your Clinician

Immediately: Severe abdominal pain (especially radiating to the back), signs of dehydration, vision changes in diabetic patients, signs of allergic reaction.

Within a few days: Side effects substantially limiting daily function, persistent vomiting beyond 48 hours, intolerable reflux that doesn’t respond to positioning and timing adjustments.

At your next scheduled visit: Dose pacing questions, plateau review, lab monitoring schedule, long-term planning.

A licensed clinician should be involved in any decision to start, adjust, or stop therapy. Full stop.

Frequently Asked Questions

What is compounded tirzepatide?

Compounded tirzepatide is a prescription preparation produced by a licensed 503A or 503B pharmacy using tirzepatide as the active pharmaceutical ingredient. It is prescribed for individual patients based on clinical judgment. It is not the same product as branded Mounjaro or Zepbound, which are FDA-approved finished drugs manufactured by Eli Lilly.

Is compounded tirzepatide legal?

Compounding is legal under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act when conducted by licensed pharmacies meeting state and federal requirements. 503A preparations require patient-specific prescriptions. Practice standards vary between pharmacies, which is why credentialing and transparency matter.

How does it compare to brand-name tirzepatide?

The active ingredient is the same molecule. Branded products undergo FDA manufacturing oversight and carry approved labels with established dosing. Compounded preparations are not FDA-evaluated for safety or efficacy. Patients sometimes choose compounded options for cost or access reasons under prescriber guidance.

Who is a candidate for compounded tirzepatide?

Candidacy is determined by a licensed clinician reviewing medical history, current medications, BMI, and metabolic markers. Standard exclusions include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, severe gastroparesis, active pancreatitis history, and pregnancy.

How is it administered?

Subcutaneous injection once weekly into the abdomen, thigh, or upper arm. Injection site rotation is recommended. Patients self-administer at home after initial training, typically using insulin-style syringes drawn from a multi-dose vial.

How long does treatment usually last?

Clinical trials demonstrated continued weight loss through 72 weeks, with peak benefit emerging between months 9 and 12. Many patients continue beyond a year on a maintenance dose. Discontinuation without lifestyle support often results in partial weight regain.

Can I switch between compounded and branded tirzepatide?

Switching is clinically feasible since the active molecule is identical. Your prescriber should manage the transition to ensure dose continuity and monitor for any differences in response or tolerability.

Important regulatory note. Compounded tirzepatide is not FDA-approved. It is prepared by licensed 503A or 503B pharmacies for individual patients based on a prescriber’s clinical judgment. Compounded preparations are not evaluated by the FDA for safety, efficacy, or quality the way branded products are. Research suggests outcomes vary between patients, and any decision to begin, modify, or discontinue therapy should occur in coordination with a licensed clinician who can review your medical history, current medications, and laboratory values.